Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-06-20
2006-06-20
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S145100, C424S178100, C530S387100, C530S388100, C530S387300, C530S388230, C530S389200
Reexamination Certificate
active
07063840
ABSTRACT:
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
REFERENCES:
patent: 4054646 (1977-10-01), Giaever
patent: WO 94/11499 (1994-05-01), None
BLOOD, vol. 80, No. 10, issued Nov. 15, 1992, Korhonen et al., “Enhanced Expression of thetieReceptor Tyrosine Kinase in Endothelial Cells During Neovascularization”, pp. 2548-2555.
Molecular and Cellular Biology, vol. 12, No. 14, issued Apr. 1992, Partanen et al., “A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains”, pp. 1698-1707.
NATURE, vol. 376, No. 6, issued Jul. 6, 1995, Sato et al., “Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation”, pp. 70-74.
ONCOGENE, vol. 8, 1993, Dumont et al., “The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors”, pp. 1293-1301.
ONCOGENE, vol. 8, 1993, Maisonpierre et al., “Distinct rat genes with related profiles of expression define TIE receptor tyrosine kinase family”, pp. 1631-1637.
Proc. Natl. Acad. Sci., vol. 87, issued Nov. 1990, Partanen et al., “Putative tyrosine kinases expressed in K562 human leukemia cells”, pp. 8913-8917.
Proc. Natl. Acad. Sci., vol. 90, issued Oct. 1993, Sato, et al., “tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system”, pp. 9355-9358.
Aldrich Thomas H.
Bruno Joanne
Davis Samuel
Goldfarb Mitchell
Jones Pamela F.
Gregg, Esq. Valeta
Mertz Prema
Regeneron Pharmaceuticals Inc.
LandOfFree
TIE-2 ligands, methods of making and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TIE-2 ligands, methods of making and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TIE-2 ligands, methods of making and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3689219